FDA's Woodcock Suggests Extending Question-Based Review to New Drugs
This article was originally published in The Gold Sheet
Question-based review for new drugs is a great idea, FDA’s Woodcock says.
You may also be interested in...
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
Agency must plan to ensure that a growing backlog of surveillance inspections does not impede its ability to conduct inspections at high-risk sites, GAO official says.